

7 July 2022

Barbara Lim
Adviser, Listing Compliance (Perth)
Australian Securities Exchange
Level 40, Central Park
152 St Georges Terrace
Perth WA 6000
BY EMAIL: Barbara.lim@asx.com.au, tradinghaltspert@asx.com.au

Dear Barbara Lim

Request for Extension to Voluntary Suspension

Neurotech International Limited (ASX: NTI) ('Company') requests to extend the current voluntary suspension in place on its securities.

The Company advises that:

- a) it is seeking this extension to its voluntary suspension pending an announcement regarding the results of its Phase I/II clinical study of the NTI164 strain in paediatric Autism Spectrum Disorder. ("Announcement");
- b) the Company wishes the voluntary suspension to remain in place until such time as the Announcement is released to the market, or until the commencement of trade on Friday 8 July 2022; and
- c) the Company is not aware of any reason why its request for an extension to the voluntary suspension should not be granted.

This request has been authorised by the Chairman of Neurotech International Limited.

Yours Faithfully,



Brian Leedman
Chairman